[Serial changes in serum CA 19-9 levels in pancreatic cancer].
Levels of a new carbohydrate antigen CA 19-9, which is a monosialoganglioside identified by a monoclonal antibody, were measured in 41 patients with pancreatic cancer and these serial changes were investigated. To provide a contrast, the serum CEA levels were compared with the serum CA 19-9 levels. As the result of this study, it was found that the serial changes of the serum levels of CA 19-9 were more correlative to the clinical course of these patients with pancreatic cancer than those of the serum CEA levels.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen